1. Home
  2. MSDL vs KTTA Comparison

MSDL vs KTTA Comparison

Compare MSDL & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MSDL
  • KTTA
  • Stock Information
  • Founded
  • MSDL 2019
  • KTTA 2020
  • Country
  • MSDL United States
  • KTTA United States
  • Employees
  • MSDL N/A
  • KTTA N/A
  • Industry
  • MSDL
  • KTTA Biotechnology: Pharmaceutical Preparations
  • Sector
  • MSDL
  • KTTA Health Care
  • Exchange
  • MSDL NYSE
  • KTTA Nasdaq
  • Market Cap
  • MSDL 1.7B
  • KTTA 2.8M
  • IPO Year
  • MSDL N/A
  • KTTA 2021
  • Fundamental
  • Price
  • MSDL $19.29
  • KTTA $0.72
  • Analyst Decision
  • MSDL Hold
  • KTTA
  • Analyst Count
  • MSDL 5
  • KTTA 0
  • Target Price
  • MSDL $20.00
  • KTTA N/A
  • AVG Volume (30 Days)
  • MSDL 419.4K
  • KTTA 192.8K
  • Earning Date
  • MSDL 01-01-0001
  • KTTA 08-12-2025
  • Dividend Yield
  • MSDL 11.75%
  • KTTA N/A
  • EPS Growth
  • MSDL N/A
  • KTTA N/A
  • EPS
  • MSDL N/A
  • KTTA N/A
  • Revenue
  • MSDL N/A
  • KTTA N/A
  • Revenue This Year
  • MSDL $1,597.39
  • KTTA N/A
  • Revenue Next Year
  • MSDL $15.10
  • KTTA N/A
  • P/E Ratio
  • MSDL N/A
  • KTTA N/A
  • Revenue Growth
  • MSDL N/A
  • KTTA N/A
  • 52 Week Low
  • MSDL $17.59
  • KTTA $0.70
  • 52 Week High
  • MSDL $23.68
  • KTTA $7.50
  • Technical
  • Relative Strength Index (RSI)
  • MSDL 47.53
  • KTTA 33.76
  • Support Level
  • MSDL $18.85
  • KTTA $0.71
  • Resistance Level
  • MSDL $19.35
  • KTTA $0.76
  • Average True Range (ATR)
  • MSDL 0.27
  • KTTA 0.04
  • MACD
  • MSDL -0.03
  • KTTA 0.01
  • Stochastic Oscillator
  • MSDL 50.28
  • KTTA 8.59

About MSDL MORGAN STANLEY DIRECT LENDING FUND

Morgan Stanley Direct Lending Fund is a fund whose investment objective is to achieve attractive risk-adjusted returns via current income and to a lesser extent, capital appreciation by investing predominantly in directly originated senior secured term loans issued by U.S. middle-market companies backed by private equity sponsors. It invests predominantly in directly originated senior secured term loans including first lien senior secured term loans including unitranche loans and second lien senior secured term loans, with the balance of the investments expected to be in higher-yielding assets such as mezzanine debt, unsecured debt, equity investments and other opportunistic asset purchases.

About KTTA Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).

Share on Social Networks: